Equillium, Inc. (EQ) News

Equillium, Inc. (EQ): $0.69

0.03 (-3.71%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add EQ to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#22 of 349

in industry

Filter EQ News Items

EQ News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest EQ News From Around the Web

Below are the latest news stories about EQUILLIUM INC that investors may wish to consider to help them evaluate EQ as an investment opportunity.

EQ Bank Card launches in Québec as Carte Banque EQ

EQ Bank (Banque EQ in Québec) is offering Québec customers a new way to earn, save and spend their money, with the introduction of its popular EQ Bank Card1 (Carte Banque EQ). Customers can use the card to withdraw cash for free at any ATM in the country, earn cash back on their spending, earn high interest on their card balance, and travel without paying foreign currency conversion fees.

Yahoo | November 20, 2023

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

LA JOLLA, Calif., November 13, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR). The data presented by Dr. Kenneth Kalunian, Professor, Medicine, UCSD School

Yahoo | November 13, 2023

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif., November 08, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates.

Yahoo | November 8, 2023

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

LA JOLLA, Calif., November 06, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study in lupus nephritis patients was presented at the annual meeting of the American Society of Nephrology (ASN). The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine

Yahoo | November 6, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

LA JOLLA, Calif., October 19, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that abstracts were accepted for poster presentations at the annual meetings of the American Society of Nephrology (ASN) and the American College of Rheumatology (ACR). ASN is taking place at the Pennsylvania Convention Center in Philadelphia, PA, November 1 – 5, and ACR is taking p

Yahoo | October 19, 2023

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

LA JOLLA, Calif., October 16, 2023--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor in development to target IL-15 and IL-21. The symposium, bringing together leaders in peptide research from academia and industry to fo

Yahoo | October 16, 2023

Equillium to Host Analyst & Investor Day

LA JOLLA, Calif., October 03, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host a virtual analyst and investor day on Monday, October 16, 2023 at 9 a.m. PT / 12:00 p.m. ET.

Yahoo | October 3, 2023

Equillium to Present at the JonesTrading 2023 Healthcare Summit

LA JOLLA, Calif., October 02, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the JonesTrading 2023 Healthcare Summit taking place October 9 - 11 at the Eden Roc hotel in Miami, Florida.

Yahoo | October 2, 2023

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

LA JOLLA, Calif., September 20, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference and the LD Micro Main Event Conference.

Yahoo | September 20, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!